Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities…
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted…
Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims…
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY…
Represents a $0.15 Per Share Increase Over 2023 Special DividendNEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc.…
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7)…
Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast’s time…
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc.…
Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3%Appointed Rob Claypoole as President and Chief Executive Officer, bringing…
A review of Russian and English literature suggests that Appili’s biodefense program ATI-1701 may have a role in preventing tularemia…